Search - tctmd.com

Displaying 41 - 60 of 79

Sort: Relevancy | Date

Making the Case for Sex-Specific CVD Guidelines

News Daily News

Making the Case for Sex-Specific CVD Guidelines

July 08, 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

News Conference News ESC Heart Failure 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

July 06, 2021

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

July 06, 2021

IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients

News Conference News ESC Heart Failure 2021

IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients

June 30, 2021

Periprocedural MIs Associated With PCI Prognostically Relevant: ESC/EAPCI

News Daily News

Periprocedural MIs Associated With PCI Prognostically Relevant: ESC/EAPCI

Michael O'Riordan

June 10, 2021

A New Biomarker to Diagnose Acute Myocarditis?

News Daily News

A New Biomarker to Diagnose Acute Myocarditis?

June 03, 2021

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

News Daily News

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

June 03, 2021

June 2021 News Roundup

News Opinion CV Team Dispatch

June 2021 News Roundup

June 01, 2021

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

May 27, 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

News Conference News ACC 2021

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

May 17, 2021

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

Presentation ACC 2021

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

Presenter: Deepak L. Bhatt

May 17, 2021

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Presentation ACC 2021

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Presenter: Adam DeVore

May 17, 2021

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

News Conference News ACC 2021

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

May 16, 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

May 15, 2021

AI-ECG Allows for Early Diagnosis of Low EF

News Daily News

AI-ECG Allows for Early Diagnosis of Low EF

Yael L. Maxwell

May 10, 2021

ISCHEMIA: PCI/CABG Has Early Hospitalization ‘Tax’ but Equals Meds Later

News Conference News SCAI 2021

ISCHEMIA: PCI/CABG Has Early Hospitalization ‘Tax’ but Equals Meds Later

Michael O'Riordan

May 06, 2021

FDA Approves Dapagliflozin for CKD Patients

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.